VCRE (61) VRDN (45) IDYA (45) DYN (40) ⌘ Pro Terminal →

Nurix Therapeutics Inc. (NRIX) — RQD Stock Rating Cockpit

$27.12 -0.51% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $27.04

Nurix Therapeutics Inc. (NRIX) carries a Roarable Rating of D- (Sell) with 42/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D- • SELL / AVOID Cap $2.96B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $27.04 (-0.28%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (42/100 · D-) historically underperformed SPY in 71% of rolling 90-day windows (-7.0% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D-

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-7.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NRIX)Realized 20D OHLCV Swing Band: ±11.3%

Deterministic 5-Pillar Attribution (42/100 Composite)

🔍 WHY NRIX SCORES 42/100 (D-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (26% of score)

Altman Z-Score 9.52 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 3/9

▲ #2 Bullish Driver: Whale & Options Positioning+10/20 pts (24% of score)

20D Institutional Volume Accumulation (±11.3% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$22.35+9.3% Next Q

Q2 (-2Q)

Grade E$24.42+3.8% Next Q

Q3 (-1Q)

Grade E$25.34+7% Next Q

Current

Grade D-$27.12-7% Hist 90D α

Trajectory: E (34) → D- (42)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a NRIX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While NRIX currently carries a cautious 42/100 (D-) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($24.98) and Max Pain ($28.48) forces dealer call-delta covering toward $29.70.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $NRIX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “NRIX Beats Next Quarter EPS Consensus (Nov 29, 2026) & Holds Above 200D SMA”

YES 42%NO 58%Trade / Inspect Odds →

RSI-14 MOMENTUMBULLISH MOMENTUM

63.830 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

9.52>3.0 Fortress Safe

PIOTROSKI F-SCOREWEAK QUALITY (1–4)

3 / 99-Pt Accounting

52-WEEK LASER RANGE93% OF RANGE

L: $12$27.12H: $28

1. Money & Cash Health● WEAK

Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 8 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 13 / 40

3. Hidden Risks & Market Weather● WARNING

SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D+RQD 21 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

2-of-3 JEV AI Jury Bearish Warning on NRIX

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

BEARISH (40)

-35.0% ROIC with 42.0% gross margin and -8.89% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (55)

Altman-Z 9.52 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

BEARISH (38)

13/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like NRIX

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.
!Sensitive to high interest rates and tighter Federal Reserve market liquidity.
!Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring NRIX)

✓Walkthrough of NRIX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NRIX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +62.40%📐 HORIZONTAL RANGE

2026-10-30O $26.90H $27.12L $25.97C $27.12VOL 2.31M

RES: $33.77SUP: $21.23SMA50: $24.98SMA200: $20.18

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NRIX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NRIX Butterfly Map → + Track NRIX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +54.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NRIX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NRIX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NRIX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NRIX)

Health Care Rank #570 of 1016 ⚔️ VCRE vs NRIX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (NRIX vs. VCRE, VRDN, IDYA, DYN)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Nurix Therapeutics Inc. (NRIX) ranks #570 by composite RQD confidence (42/100, grade D-) and #210 by equity capitalization ($2.96B). Within this direct 5-issuer industry benchmark cohort, NRIX leads on earnings valuation at N/A trailing P/E, while IDYA leads on capital efficiency and profitability with -13.8% ROIC and — gross margin. VCRE currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with NRIX at 42/100 (D-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NRIX ACTIVE Nurix Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.51%	$2.96B	Benchmark Subject
VCRE Vicore Pharma Holding AB	C-	61/100	—	—	—	+4.56%	$2.87B	/vcre-vs-nrix →
VRDN Viridian Therapeutics Inc.	D	45/100	—	—	-35.0%	+2.18%	$2.81B	/vrdn-vs-nrix →
IDYA IDEAYA Biosciences Inc.	D	45/100	—	—	-13.8%	-3.15%	$3.17B	/idya-vs-nrix →
DYN Dyne Therapeutics Inc.	D-	40/100	—	—	-35.0%	+0.35%	$3.18B	/dyn-vs-nrix →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-11-30 • CIK 0001549595

In its most recent audited fiscal period (FY2025, filed 2025-11-30), Nurix Therapeutics Inc. (NRIX) reported GAAP revenue of $84.0M (+54.0% vs. FY2024 revenue of $54.5M , and +9.1% cumulative change since FY2023) , GAAP net income of -$264.5M, operating cash flow of -$249.5M, and free cash flow of -$263.5M (-44.9% YoY). On the balance sheet, NRIX closed FY2025 with $688.1M in total assets against $0 in total debt (Altman Z-Score: 9.52, Piotroski F-Score: 3/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-11-30	$84.0M	-$264.5M	-$249.5M	-$263.5M	$688.1M	—
FY2024 (FY)	2024-11-30	$54.5M	-$193.6M	-$172.6M	-$181.9M	$669.3M	—
FY2023 (FY)	2023-11-30	$77.0M	-$143.9M	-$81.4M	-$81.4M	—	—

3. NRIX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NRIX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nurix Therapeutics Inc. (NASDAQ: NRIX) is rated D- (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 42/100 at a spot price of $27.12 (-0.51% 1D, market cap $2.96B). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 10/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, NRIX ranks #570 in composite RQD confidence.

How does NRIX compare to VCRE and VRDN in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), NRIX carries a Roarable D- (42/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, VCRE (Vicore Pharma Holding AB) holds a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $2.87B) and VRDN (Viridian Therapeutics Inc.) posts a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.81B). Among the 5-stock peer group, NRIX leads on earnings multiple (N/A) while IDYA leads on capital efficiency (-13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NRIX?

Per NRIX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-11-30, CIK 0001549595), Nurix Therapeutics Inc. generated $84.0M in revenue (+54.0% YoY), -$264.5M in net income, and -$263.5M in free cash flow against $688.1M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NRIX trading relative to its 50-day, 200-day, and 52-week technical levels?

NRIX last traded at $27.12 (-0.51% on volume of 2,375,225 shares), positioning the stock +8.57% above its 50-day simple moving average ($24.98) and +34.39% above its 200-day simple moving average ($20.18). Across its 52-week range of $11.67 to $28.23, NRIX sits at the 93.3% percentile with a 14-day RSI of 63.8 (BULLISH MOMENTUM) and an implied next-earnings move of ±11.3% ($24.06 to $30.18).

NRIX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell NRIX stock right now?

Nurix Therapeutics Inc. (NRIX) currently earns a Roarable Rating of D- (Sell — SELL) with 42/100 RQD Confidence. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.

What is NRIX's 12-month price target and RQD AI Jury consensus?

NRIX's 12-month base price target is $25.17 (range $19.63 to $29.7), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: NRIX RQD Cockpit NRIX 12M Forecast NRIX Earnings & Move NRIX Dividends & DRIP NRIX Insiders & 13F NRIX Whale Options NRIX Profit Sankey NRIX News & Why